Journal: Antimicrobial Agents and Chemotherapy
Article Title: Efficacy of PLD-118, a Novel Inhibitor of Candida Isoleucyl-tRNA Synthetase, against Experimental Oropharyngeal and Esophageal Candidiasis Caused by Fluconazole-Resistant C. albicans
Figure Lengend Snippet: Response of experimental OPEC caused by fluconazole-resistant Candida albicans in immunocompromised rabbits to antifungal therapy measured by mean log concentration of organism in the stomach and duodenum. Data for untreated controls (control) ( n = 12), rabbits treated with PLD at 4 (PLD4; n = 8), 10 (PLD10; n = 8), 25 (PLD25; n = 8), and 50 mg/kg/day (PLD50; n = 8), rabbits treated with DAMB at 0.5 mg/kg/day (DAMB; n = 4), and rabbits treated with FLC at 2 mg/kg/day ( n = 10) are shown. Values are given as means ± SEM. Comparisons were to untreated controls by ANOVA with Dunn's correction for multiple comparisons or by the Mann-Whitney U test, as appropriate (*, P ≤ 0.05; †, P ≤ 0.01; ¶, P
Article Snippet: To characterize the in vitro pharmacodynamics and potential fungicidal activity of PLD-118 (Pliva Pharmaceutical Industry, Inc., Zagreb, Croatia), time-kill assays were performed in the same fashion for all four C. albicans isolates, with fluconazole (Roerig-Pfizer, New York, N.Y.) used as a treatment control.
Techniques: Concentration Assay, MANN-WHITNEY